publication . Article . 2017

Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data.

Attaei, Marjan W; Khatib, Rasha; McKee, Martin; Lear, Scott; Dagenais, Gilles; Igumbor, Ehimario U; AlHabib, Khalid F; Kaur, Manmeet; Kruger, Lanthe; Teo, Koon; ...
Open Access English
  • Published: 05 Sep 2017
  • Publisher: Elsevier
  • Country: United Kingdom
Abstract
BACKGROUND: Hypertension is considered the most important risk factor for cardiovascular diseases, but its control is poor worldwide. We aimed to assess the availability and affordability of blood pressure-lowering medicines, and the association with use of these medicines and blood pressure control in countries at varying levels of economic development. METHODS: We analysed the availability, costs, and affordability of blood pressure-lowering medicines with data recorded from 626 communities in 20 countries participating in the Prospective Urban Rural Epidemiological (PURE) study. Medicines were considered available if they were present in the local pharmacy wh...
Related Organizations
Funded by
CIHR
Project
  • Funder: Canadian Institutes of Health Research (CIHR)
Download from
36 references, page 1 of 3

1 Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 2016; 388: 2665-712.

2 Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370: 591-603.

4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Chow KC, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310: 959-68.

Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4: 393-404.

James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-20.

WHO. The selection of essential drugs. 1977. http://apps.who.int/ medicinedocs/documents/s20185en/s20185en.pdf (accessed Sept 20, 2016).

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905-12.

Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 2005; 42: 17-25. [OpenAIRE]

N Engl J Med 2016; 374: 2009-20.

N Engl J Med 2016; 374: 2021-31.

Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S; PURE Investigators-Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J 2009; 158: 1-7.e1.

Corsi DJ, Subramanian S V, Chow CK, et al. Prospective Urban Rural Epidemiology (PURE) study: baseline characteristics of the household sample and comparative analyses with national data in 17 countries. Am Heart J 2013; 166: 636-46.e4.

Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378: 1231-43.

Yusuf S, Rangarajan S, Teo K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med 2014; 371: 818-27.

Khatib R, McKee M, Shannon H, et al. Availability and afordability of cardiovascular disease medicines and their efect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 2016; 387: 61-69.

36 references, page 1 of 3
Abstract
BACKGROUND: Hypertension is considered the most important risk factor for cardiovascular diseases, but its control is poor worldwide. We aimed to assess the availability and affordability of blood pressure-lowering medicines, and the association with use of these medicines and blood pressure control in countries at varying levels of economic development. METHODS: We analysed the availability, costs, and affordability of blood pressure-lowering medicines with data recorded from 626 communities in 20 countries participating in the Prospective Urban Rural Epidemiological (PURE) study. Medicines were considered available if they were present in the local pharmacy wh...
Related Organizations
Funded by
CIHR
Project
  • Funder: Canadian Institutes of Health Research (CIHR)
Download from
36 references, page 1 of 3

1 Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 2016; 388: 2665-712.

2 Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370: 591-603.

4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Chow KC, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310: 959-68.

Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002; 4: 393-404.

James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-20.

WHO. The selection of essential drugs. 1977. http://apps.who.int/ medicinedocs/documents/s20185en/s20185en.pdf (accessed Sept 20, 2016).

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905-12.

Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 2005; 42: 17-25. [OpenAIRE]

N Engl J Med 2016; 374: 2009-20.

N Engl J Med 2016; 374: 2021-31.

Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S; PURE Investigators-Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J 2009; 158: 1-7.e1.

Corsi DJ, Subramanian S V, Chow CK, et al. Prospective Urban Rural Epidemiology (PURE) study: baseline characteristics of the household sample and comparative analyses with national data in 17 countries. Am Heart J 2013; 166: 636-46.e4.

Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378: 1231-43.

Yusuf S, Rangarajan S, Teo K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med 2014; 371: 818-27.

Khatib R, McKee M, Shannon H, et al. Availability and afordability of cardiovascular disease medicines and their efect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 2016; 387: 61-69.

36 references, page 1 of 3
Any information missing or wrong?Report an Issue